Test drug combination for recurrent brain tumor growth
Part of Cancer clinical trials.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old
- You have a confirmed glioma in the brain, such as recurrent glioblastoma or lower-grade gliomas
- Your cancer has returned and is confirmed by biopsy/surgery at least 2 weeks ago or by MRI showing a measurable enhancing tumor area
- You already had standard radiation plus chemotherapy, and at least 3 months have passed since radiation
- You can do daily activities fairly well (Karnofsky score 60 or higher) and are likely to live at least 12 weeks
- Your blood tests and organ tests (liver, kidneys, blood counts) and heart rhythm on ECG meet study limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
Hear when a new Glioblastoma, Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.